Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 22 May 2024
Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 6 July 2022
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31) [ID6598]Status:Awaiting developmentProgramme:Highly specialised technologies guidanceExpected publication date: TBC